ArticleBlood cancer journal2017

The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways.

L Besse et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.